Specialized Therapies | HIV and Oncology
Press Releases and Company Announcements
Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference
Theratechnologies Trogarzo® Data at AIDS 2022 Shows Potential for Improved Treatment Regimens
Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement
Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies. We currently have a Phase 1 clinical trial underway in oncology using our novel and proprietary SORT1+ Technology™. We also plan to initiate a Phase 3 clinical trial to evaluate tesamorelin as a potential treatment for NASH, a severe liver condition which affects a growing number of people around the world.
Making a difference through innovation
Theratechnologies makes a difference in the lives of patients through the development and commercialization of products addressing important unmet medical needs.